Journal
NEUROLOGICAL SCIENCES
Volume 32, Issue 5, Pages 841-847Publisher
SPRINGER-VERLAG ITALIA SRL
DOI: 10.1007/s10072-011-0657-6
Keywords
Sporadic inclusion-body myositis; Simvastatin; Pilot clinical trial
Categories
Funding
- Istituto Superiore di Sanita [ISS 526D/15]
- Don Carlo Gnocchi ONLUS Foundation
- Catholic University
Ask authors/readers for more resources
Sporadic inclusion-body myositis (s-IBM) is a chronic progressive inflammatory myopathy leading to severe disability. It has been suggested that statins may benefit s-IBM patients based on their pleiotropic effects on autoimmunity and possible adverse influence of increased cholesterol on muscle pathological changes. We carried out a pilot, open-label trial to evaluate safety and tolerability of oral simvastatin in s-IBM patients. Fourteen patients were treated with 40 mg of simvastatin over 12 months. Primary outcome measures included the assessment tools proposed by International Myositis Outcome Assessment Collaborative Study group and the IBM-Functional Rating Scale. As additional data, we report the results obtained from muscle MRI, biopsy and oropharyngeal scintigraphy. Ten patients completed the trial and the treatment appeared safe and well tolerated. None of the patients showed a significant clinical improvement. Outcome measures used in this study proved to be valuable tools for global assessment of s-IBM patients. At present, we cannot recommend simvastatin as a treatment for s-IBM though our data may warrant a placebo-controlled study.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available